Fompé is a leading Italian biopharmaceutical company. In recent years (and without advertising), its analgesic product Oki has seen a considerable increase in its market share. This was due both to an innovative and fast acting formula and to the sale limitations that the market leader had to undergo in the same time span (some side effects had been brought to evidence). Since then, Oki was suggested and prescribed until it became, in turn, the market leader in strong pain analgesics. Despite a strong competition, the company decided to capitalize on the success of Oki and stretch into the segment of light pain analgesics by launching Okitask, an OTC to be sold without prescription.